Redmile Group, LLC Chimerix Inc Transaction History

Redmile Group, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$1.3 - $2.72 $4.21 Million - $8.8 Million	-3,235,795 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $622,604 - $1.36 Million	-322,593 Reduced 9.07%	3,235,795 $7.6 Million
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $44,423 - $93,614	21,670 Added 0.61%	3,558,388 $15.4 Million
Q1 2019 May 15, 2019	SELL	$1.79 - $3.12 $50,535 - $88,083	-28,232 Reduced 0.79%	3,536,718 $7.43 Million
Q4 2018 Feb 14, 2019	SELL	$2.24 - $3.9 $58,464 - $101,790	-26,100 Reduced 0.73%	3,564,950 $9.16 Million
Q3 2018 Nov 14, 2018	BUY	$3.58 - $4.9 $5,584 - $7,644	1,560 Added 0.04%	3,591,050 $14 Million
Q2 2018 Aug 14, 2018	SELL	$4.43 - $5.14 $616,656 - $715,488	-139,200 Reduced 3.73%	3,589,490 $17.1 Million
Q1 2018 May 15, 2018	SELL	$4.65 - $5.9 $484,009 - $614,119	-104,088 Reduced 2.72%	3,728,690 $0
Q4 2017 Feb 14, 2018	SELL	$4.32 - $5.52 $1.7 Million - $2.17 Million	-392,797 Reduced 9.3%	3,832,778 $17.7 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $18.4 Million - $22.2 Million	4,225,575	4,225,575 $22.2 Million

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.